Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non-Small Cell Lung Cancer

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1467-1473

  Scarpace, Sarah L ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Breast cancer; E7389; Eribulin; Eribulin mesylate; Halaven; Halichondrin B

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DIAZEPAM; ERIBULIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MIDAZOLAM; MITOMYCIN; NIFEDIPINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TAXANE DERIVATIVE; TERFENADINE; TESTOSTERONE; VINORELBINE DITARTRATE; WARFARIN;

ALOPECIA; ANEMIA; ANOREXIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COCHRANE LIBRARY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL INFECTION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MEDLINE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PNEUMONIA; QT PROLONGATION; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SKIN INFECTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FURANS; HUMANS; KETONES; NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 84863831074     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.003     Document Type: Review

References (12)

1. Halaven [package insert] 2010, Eisai Inc, Woodcliff Lake, NJ.
2. Cortes J., O'Saughnessy J., Loesch D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011, 377:914-923. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.
3. Spira A.I., Iannotti N.O., Savin M.A., et al. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small cell lung cancer. Clin Lung Cancer 2012, 13:31-38.
4. Gitlitz B., Davies A., Belani C., et al. A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane: a California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial. J Clin Oncol 2009, 27:15s.
5. Arnold S., Moon J., Williamson S., et al. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 2009, 29:352-359.
6. Renouf D.J., Tang P.A., Major P., et al. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs 2011, 29:352-359.
7. Goel S., Mita A., Mita M., et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009, 15:4207-4212.
8. Tan A., Rubin E., Walton D., et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009, 15:4213-4219.
9. CHMP Assessment Report for Halaven eribulin European Medicines Agency, Accessed April 10, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002084/WC500105115.pdf.
10. Devriese L.A., Merqui-Roelvink M., Wanders J., et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Invest New Drugs 2012, [Epub ahead of print].
11. Michaud L.B., Eckman K. Eribulin: another new chemotherapy for breast cancer. HemOnc Today Accessed January 4, 2012. http://www.hemonctoday.com/article.aspx?rid=81883.
12. Final Appraisal Determination: eribulin for the treatment of advanced or metastatic breast cancer November 2011, National Institute for Health and Clinical Excellence, Accessed January 4, 2012. http://www.nice.org.uk/nicemedia/live/13238/57079/57079.pdf.